Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01422187
Recruitment Status : Completed
First Posted : August 23, 2011
Results First Posted : December 14, 2015
Last Update Posted : October 5, 2018
Information provided by (Responsible Party):

Brief Summary:
This is a multi-center trial to further extend the assessment of the safety and efficacy of taliglucerase alfa in adult subjects (≥18 years old) with Gaucher disease who have enrolled in Protocol PB-06-003. Subjects will continue to receive an intravenous (IV) infusion of taliglucerase alfa every two weeks. The duration of treatment will be a maximum of 21 months or until taliglucerase alfa is commercially available to the subject at the discretion of the Sponsor.

Condition or disease Intervention/treatment Phase
Gaucher Disease Drug: Taliglucerase alfa Phase 3

Expanded Access : An investigational treatment associated with this study is no longer available outside the clinical trial.   More info ...

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 19 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher Disease
Study Start Date : August 2011
Actual Primary Completion Date : May 2014
Actual Study Completion Date : September 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Gaucher Disease

Arm Intervention/treatment
Experimental: Taliglucerase alfa 30 units/kg
Subjects randomized to receive 30 units/kg
Drug: Taliglucerase alfa
Taliglucerase infusion every two weeks for 21 months

Experimental: Taliglucerase alfa 60 units/kg
Subjects randomized to 60 units/kg
Drug: Taliglucerase alfa
Taliglucerase infusion every two weeks for 21 months

Primary Outcome Measures :
  1. Spleen Volume [ Time Frame: 60 months ]
    Spleen volume measured by MRI

Secondary Outcome Measures :
  1. Liver Volume [ Time Frame: 60 months ]
    Liver volume by MRI

  2. Platelet Count [ Time Frame: 60 months ]
    Platelet count measure annually

  3. Hemoglobin [ Time Frame: 60 months ]
    Hemoglobin measure yearly

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Successfully completed Protocol PB-06-001 and enrolled in Protocol PB-06-003
  • The subject signs an informed consent

Exclusion Criteria:

  • Currently taking another investigational drug for any condition.
  • Presence of any medical, emotional, behavioral or psychological condition that in the judgment of the Investigator would interfere with the subject's compliance with the requirements of the study.
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Pfizer Identifier: NCT01422187    
Other Study ID Numbers: PB-06-007
First Posted: August 23, 2011    Key Record Dates
Results First Posted: December 14, 2015
Last Update Posted: October 5, 2018
Last Verified: September 2018
Keywords provided by Pfizer:
enzyme replacement therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Gaucher Disease
Lysosomal Storage Diseases, Nervous System
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Lipid Metabolism, Inborn Errors
Lysosomal Storage Diseases
Metabolic Diseases
Lipid Metabolism Disorders